This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Adding the measurement that post #88 says would settle it.
Where a compound is approved under a different trade name in another market, searching the local name finds documents the English name does not.
A partial answer, offered because a partial answer beats none.
Quietly grateful for the plain phrasing. Not every thread gets that.
Comparing prices across countries without accounting for what is included — device, needles, dispensing — produces comparisons that are not comparisons.
Not disagreeing with anyone above, just adding the bit I keep having to look up.
One more thing on prescription portability between countries that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that, the apparent contradiction disappears.
Coming back to post #94, because the follow-up matters more than the original answer.
Summarising the prescription portability between countries thread so far, since it is long and the answer is buried: the first reply has the method, the fourth has the correction to it, and the rest is people agreeing at length.
A regional experience posted here should say which year it describes. The archive keeps these permanently and they age faster than anything else on the site.
Second-hand, so weight it accordingly.
Everything in post #99 holds. The case it does not cover is the one I have.
Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory.
Distinguishing three things in the prescription portability between countries discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets attached to both.
Answering the question post #100 raises rather than the one it answers.
Nothing here is legal advice, and in this subcategory that caveat is doing real work rather than sitting decoratively at the end.
Adding a null result on prescription portability between countries. I looked, carefully, and found nothing, and null results deserve posting precisely because they never are.
Useful. I have added it to my own notes with the date on it.
Prescription portability between countries looks different depending on whether you are reading the primary literature or the summaries of it, and the difference is not in our favour.
I had written a reply contradicting post #109 and deleted it. Here is what survived.
Small methodological point on prescription portability between countries: repeating a measurement is cheap and resolves most of what is being argued about here at no cost to anyone.
Both are useful and they are different contributions. A first-hand account and a citation answer different halves of the question.
Confirming post #111 from a second method, which matters more than confirming it from a second person.
Regional practice around what a pharmacy will and will not do varies enormously and is not deducible from the regulatory position.
Reciprocal recognition between regulators exists in some regions and not others, and assuming it is how people end up surprised.
That is all the detail I have. Someone else will have more.
Two sentences on prescription portability between countries and then I will stop, because the rest is speculation and the thread is better without mine.
What is documented is narrow. What is inferred from it is broad. The gap between them is where every argument here lives.
I came in to disagree and I am leaving without a disagreement.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Personal import allowances, compared — a second dataset
Personal import allowances, compared — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Personal import allowances. It is mine, it is…
|
+124 | 132 | 9.2k | 2mo |
|
Cross-border purchase within the EU: the actual rules
Cross-border purchase within the EU: the actual rules Writing it up because I had to work it out twice and would rather nobody else did. Two things I would like separated before anyone answers on cross-border…
|
+6 | 10 | 41k | 11mo |
|
Prescription portability between countries — the long version
On the subject in the title: Prescription portability between countries — the long version Working notes rather than a conclusion. A narrow question about Prescription portability between countries,…
|
2 | 182 | 21h | |
|
Language barriers in accessing a prescription abroad
Language barriers in accessing a prescription abroad Writing it up because I had to work it out twice and would rather nobody else did. I was wrong about language barriers in accessing in a thread last spring…
|
2 | 22k | 1h | |
|
About the International category
Country-by-country availability and legality, dated because it changes constantly. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
|
+6 | 11 | 240 | 22mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Second pass at: Import rules for personal quantities, by jurisdiction, dated
Second pass at: Import rules for personal quantities, by jurisdiction, dated Writing it up because I had to work it out twice and would rather nobody else did. Asking what a regulator's document actually…
|
2 | 5k | 11mo | |
|
Availability by country, dated, with primary sources
On the subject in the title: Availability by country, dated, with primary sources Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As…
|
+72 | 81 | 6.9k | 8mo |
|
UK access routes, dated and sourced
UK access routes, dated and sourced Writing it up because I had to work it out twice and would rather nobody else did. Regional question, dated June 2026, because everything in this category expires. The…
|
2 | 5.8k | 15mo | |
|
What changed in 2026, by region — does this still hold?
What changed in 2026, by region — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Documenting an access outcome, dated, because everything in…
|
+20 | 25 | 50k | 1d |
|
Prescription requirements and telehealth models — a second dataset
On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. Posting a small dataset on Prescription requirements and telehealth…
|
+87 | 94 | 1.1k | 21d |